CaDrA: A computational framework for performing candidate driver analyses using binary genomic features
暂无分享,去创建一个
Liye Zhang | Stefano Monti | Paola Sebastiani | Vinay K. Kartha | Joseph G. Kern | Xaralabos Varelas | P. Sebastiani | S. Monti | X. Varelas | Liye Zhang | Joseph G. Kern
[1] Stefano Monti,et al. ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways , 2015, Bioinform..
[2] C. Der,et al. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.
[3] Stefano Piccolo,et al. YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.
[4] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[5] A. Frigessi,et al. Principles and methods of integrative genomic analyses in cancer , 2014, Nature Reviews Cancer.
[6] E. Kohn,et al. The MAPK pathway across different malignancies: A new perspective , 2014, Cancer.
[7] J. F. Burrows,et al. Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen , 2014, Oncogene.
[8] Douglas B. Johnson,et al. Treatment of NRAS-Mutant Melanoma , 2015, Current Treatment Options in Oncology.
[9] Ronald Simon,et al. Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. , 2010, The American journal of pathology.
[10] Xaralabos Varelas,et al. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease , 2014, Development.
[11] Justin Guinney,et al. Systematic Assessment of Analytical Methods for Drug Sensitivity Prediction from Cancer Cell Line Data , 2013, Pacific Symposium on Biocomputing.
[12] F. Cecconi,et al. Physiological and pathological roles of Apaf1 and the apoptosome , 2003, Journal of cellular and molecular medicine.
[13] Philippe P Roux,et al. Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases , 2011, Microbiology and Molecular Reviews.
[14] Douglas A. Chapnick,et al. Partners in crime: the TGFβ and MAPK pathways in cancer progression , 2011, Cell & Bioscience.
[15] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[16] F. Lozupone,et al. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma , 2006, Oncogene.
[17] Michal Sheffer,et al. Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.
[18] Eli Upfal,et al. De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.
[19] M. Yaffe,et al. TAZ: a novel transcriptional co‐activator regulated by interactions with 14‐3‐3 and PDZ domain proteins , 2000, The EMBO journal.
[20] S. Bicciato,et al. Aerobic glycolysis tunes YAP/TAZ transcriptional activity , 2015, The EMBO journal.
[21] Xaralabos Varelas,et al. The Transcriptional Regulators TAZ and YAP Direct Transforming Growth Factor β-induced Tumorigenic Phenotypes in Breast Cancer Cells*♦ , 2014, The Journal of Biological Chemistry.
[22] L. Staudt,et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.
[23] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[24] Yi Yuan,et al. Reelin Is Involved in Transforming Growth Factor-β1-Induced Cell Migration in Esophageal Carcinoma Cells , 2012, PloS one.
[25] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[26] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[27] J. O’Leary,et al. BRAFV600E: Implications for Carcinogenesis and Molecular Therapy , 2011, Molecular Cancer Therapeutics.
[28] Stefano Monti,et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.
[29] M. Sudol,et al. Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. , 1994, Oncogene.
[30] Stefano Monti,et al. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma , 2015, Molecular Cancer Research.
[31] David M. Thomas,et al. The Hippo pathway and human cancer , 2013, Nature Reviews Cancer.
[32] E. Choi,et al. Pathological roles of MAPK signaling pathways in human diseases. , 2010, Biochimica et biophysica acta.
[33] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[34] Antonio Rosato,et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.
[35] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[36] Roded Sharan,et al. Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..
[37] Yan Zhou,et al. Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. , 2016, Cell reports.
[38] Jun S. Liu,et al. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans , 2015, Science.
[39] Gabriela Alexe,et al. Characterizing genomic alterations in cancer by complementary functional associations , 2016, Nature Biotechnology.
[40] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[41] C. Heldin,et al. Non-Smad TGF-β signals , 2005, Journal of Cell Science.
[42] Wei Huang,et al. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer. , 2010, Human pathology.
[43] Joshua M. Stuart,et al. Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.
[44] Laura M. Heiser,et al. Modeling precision treatment of breast cancer , 2013, Genome Biology.
[45] W. Grady,et al. TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. , 2009, Biochimica et biophysica acta.
[46] C. Heldin,et al. Non-Smad TGF-beta signals. , 2005, Journal of cell science.
[47] S. Dupont,et al. The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.
[48] Kun-Liang Guan,et al. The emerging roles of YAP and TAZ in cancer , 2015, Nature Reviews Cancer.
[49] Ying E. Zhang,et al. Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.
[50] Vivienne Marsh,et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.
[51] W. Gerald,et al. Apaf-1 expression in malignant melanoma , 2006, Cell Death and Differentiation.